All In Biotech

Drug Trial Radar · NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Dec 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 17,190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

17,190

Actual

Start

Apr 25, 2013

Primary completion

Sep 11, 2018

Study completion Sep 11, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
First posted
Nov 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent
  • High Risk for Cardiovascular Event

Interventions

  • Dapagliflozin 10 mgDrug

    Oral dose (od)

  • Placebo tabletDrug

    Oral dose (od)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic StrokeTime frame: up to 5.2 years
  2. Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.Time frame: up to 5.2 years

Locations

805 sites in 34 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Athens, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Alhambra, California

  • Research Site

    Bakersfield, California

  • Research Site

    Greenbrae, California

  • Research Site

    Huntington Park, California

  • Research Site

    La Mesa, California

  • Research Site

    Lomita, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Diego, California

  • Research Site

    San Marino, California

  • Research Site

    San Ramon, California

  • Research Site

    Torrance, California

  • Research Site

    Ventura, California

  • Research Site

    Vista, California

  • Research Site

    Fort Collins, Colorado

  • Research Site

    Golden, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Bristol, Connecticut

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Stamford, Connecticut

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Seaford, Delaware

  • Research Site

    Wilmington, Delaware

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Bradenton, Florida

  • Research Site

    Chiefland, Florida

  • Research Site

    Clearwater, Florida

Showing 40 of 805 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.